By Christian Woelbeling, Thomas Zimmer, and Christoph Herwig
It’s no question that in the digital age, pharma and biotech production must be supported by manufacturing execution systems (MES). These systems digitize end-to-end pharma manufacturing processes – from receiving goods via warehousing through to production and packaging. Using MES results in process improvements and significant efficiency savings.
Pharma manufacturing without MES is a risky strategy
If you are still documenting your pharma production processes on paper, there is a constant potential threat of human errors, data integrity violations and warning letters. An incident can put your entire production on hold. So if you think the implementation of MES just costs money and lacks ROI, think twice.